Content |
Foundation Medicine — develops and sells genomic tests for screening of cancer tumors. The company is founded in 2010, and three years later it became public.
Flagship product of Foundation Medicine is Foundation Medicine — the test for complex genomic profiling of tumors with various means of accompanying diagnostics of patients with the NMRL some types, melanomas, a colorectal cancer, ovarian cancer or a breast cancer, for the purpose of identification of those from them to whom treatment can bring benefit.
The platform of molecular information Foundation Medicine is designed to optimize treatment of patients, providing doctors, scientists and developers of medicines with necessary data with the purpose of development of molecular medicine in the field of oncology.
History
2018: Roche increases a share in Foundation Medicine up to 100% for $2.4 billion
On June 19, 2018 Roche which long time is engaged in development of medicine for cancer therapy, announced increase up to 100% of the share in Foundation Medicine. For $2.4 billion 44% of stocks therefore the developer of means of gene diagnostics of cancer cells was estimated at $5.3 billion were purchased. It is 29% more than the cost of the company a day before the declaration of the transaction with Roche.
It is going execute all formalities concerning Foundation Medicine sale in the second half of 2018. At this Foundation Medicine will remain the autonomous company as a part of Roche.
The analyst of Vontobel Stefan Schneider considers that the transaction will very well be approved with a position of Roche as the leading developer of remedies for cancer on the basis of the analysis of genetic profiles.
 | It not only on a hand to patients, but also should allow Roche to develop more effective medicines of directional effect that finally will improve development of medicines and will reduce the prices — the expert believes.[1] |  |
2015: Roche takes 56% of the shares Foundation Medicine for $1 billion
In 2015 Roche acquired 56% of the shares Foundation Medicine for $1 billion
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |